Skip to main content
. 2022 Dec 2;83(6):694–701. doi: 10.1055/a-1963-7511

Table 2 Univariate analysis of pathologic complete response (pCR) rates according to patient characteristics.

pCR no pCR P value
* chi-squared-test; pCR = pathologic complete response; ER = estrogen receptor; PR = progesterone receptor
All Patients, N 77 (62.1) 47 (37.9)
Mean age, years (SD) 51.8 (9.7) 52.9 (8.8) 0.554
Tumor size, N (%) 0.051

  • T1

 20 (80.0) 5 (20.0)

  • T2

 48 (60.8) 31 (39.2)

  • T3–4

 9 (45.0) 11 (55.0)
Nodal involvement, N (%) 0.195

  • pN−

 37 (68.5) 17 (31.5)

  • pN+

 40 (57.1) 30 (42.9)
Grading, N (%) 0.611

  • G2

 26 (65.0) 14 (35.0)

  • G3

 50 (60.2) 33 (39.8)
ER status, N (%) 0.005

  • negative

 41 (75.9) 13 (24.1)

  • positive

 36 (51.4) 34 (48.6)
PR status, N (%) 0.005

  • negative

 54 (72.0) 21 (28.0)

  • positive

 23 (46.9) 26 (53.1)
HR status, N (%) 0.002

  • negative

 41 (77.4) 12 (22.6)

  • positive

 36 (50.7) 35 (49.3)
HER2 status, N (%) 0.046

  • Score 2+

 9 (42.9) 12 (57.1)

  • Score 3+

 68 (66.0) 35 (34.0)
Anthracyclines, N (%) 0.467

  • no

 8 (72.7) 3 (27.3)

  • yes

 69 (61.6) 43 (38.4)
Dual HER2 blockade, N (%) 0.215

  • no

 14 (51.9) 13 (48.1)

  • yes

 63 (64.9) 34 (35.1)